Login
Companies $OGN
$13.90 +$0.00 (0.0%) After hours
Organon & Co. logo

Organon & Co.

organon.com

What Do They Do?

Sells prescription medicines and biosimilars across women’s health and general medicine to drug wholesalers and retailers, healthcare providers, and government and managed-care buyers.

How Do They Make Money?

Organon sells medicines to wholesalers, retailers, hospitals and other buyers; customers pay when ownership of the products passes to them.

revenue
SegmentShareRevenue
Nexplanon/Implanon NXT
Sold outright

15%
FY2022: 14%
Follistim AQ
Sold outright
4.3%
FY2022: 3.7%
NuvaRing
1.5%
FY2022: 3.6%
Ganirelix Acetate Injection
1.6%
FY2022: 2.0%
Marvelon/Mercilon
2.0%
FY2022: 1.8%
Jada
1.2%
FY2022: 0.3%
Other Women's Health
2.8%
FY2022: 2.2%
Renflexis
Sold outright
4.0%
FY2022: 3.7%
Hadlima
Sold outright
3.7%
FY2022: 0.3%
Ontruzant
1.6%
FY2022: 2.0%
Brenzys
1.3%
FY2022: 1.2%
Other Biosimilars
0.5%
Atozet
Sold outright
5.2%
FY2022: 7.4%
Zetia
Sold outright
5.5%
FY2022: 6.0%
Cozaar/Hyzaar
Sold outright
3.5%
FY2022: 5.2%
Vytorin
1.6%
FY2022: 2.1%
Rosuzet
0.4%
FY2022: 1.2%
Other Cardiovascular
2.0%
FY2022: 2.4%
Singulair
Sold outright
4.1%
FY2022: 6.7%
Nasonex
Sold outright
4.2%
FY2022: 4.2%
Dulera
2.5%
FY2022: 2.9%
Clarinex
2.0%
FY2022: 2.0%
Other Respiratory
0.8%
FY2022: 1.0%
Arcoxia
Sold outright
4.3%
FY2022: 3.9%
Fosamax
2.3%
FY2022: 2.5%
Diprospan
2.4%
FY2022: 2.0%
Vtama
2.1%
FY2022: 0.0%
Other Non-Opiod Pain, Bone and Dermatology
Sold outright
4.8%
Propecia
1.9%
FY2022: 2.0%
Emgality
2.8%
Proscar
1.6%
FY2022: 1.6%
Other
Sold outright
5.4%
FY2022: 5.3%
Other
1.3%
FY2022: 2.4%

Who Are Their Customers?

Organon sells mainly to drug wholesalers and retailers, healthcare institutions such as hospitals and clinics, and government and managed-care organizations. It also uses third-party distributors and agents in smaller markets.

Do Revenues Turn Into Profits?

Yes. It kept 3 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.

Net income, FY2025
3% of revenue
▼ −78% vs FY2024 ($864M, 13%)
Free cash flow, FY2025
9% of revenue
▼ −30% vs FY2024 ($764M, 12%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −2%
vs $1.6B in Q3 FY2025
Net income
▲ +3%
vs $160M in Q3 FY2025
Nexplanon/Implanon NXT share of revenue vs 13.9% in Q3 FY2025
  • Apr 27, 2026 Sun Pharma agreed to acquire Organon for cash The agreement sets cash consideration at $14.00 per share, subject to regulatory and stockholder approvals.

Flat. Revenue was $6.2B in FY2025, about the same as the $6.3B of FY2021.

Jada divestiture The older report included the Jada System in the women’s health portfolio; the latest report says Organon divested it to Laborie.

Revenue over time
Nexplanon/Implanon NXT Follistim AQ NuvaRing Ganirelix Acetate Injection Marvelon/Mercilon Jada Other Women's Health Renflexis Hadlima Ontruzant Brenzys Other Biosimilars Atozet Zetia Cozaar/Hyzaar Vytorin Rosuzet Other Cardiovascular Singulair Nasonex Dulera Clarinex Other Respiratory Arcoxia Fosamax Diprospan Vtama Other Non-Opiod Pain, Bone and Dermatology Propecia Emgality Proscar Other Other Aybintio Emgality/Rayvow Other Non-Opioid Pain, Bone and Dermatology
$10B$5B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support